scholarly journals Adverse reactions to Pfizer‐BioNTech vaccination of healthcare workers at Malta’s state hospital

2021 ◽  
Author(s):  
Sarah Cuschieri ◽  
Michael Borg ◽  
Steve Agius ◽  
Jorgen Souness ◽  
Andre Brincat ◽  
...  
Keyword(s):  
State Hospital ◽  
Healthcare Workers ◽  
Adverse Reactions

scholarly journals Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in South Korea

2021 ◽  
Vol 36 (21) ◽  
Author(s):  
Yun Woo Lee ◽  
So Yun Lim ◽  
Ji-Hyang Lee ◽  
Joon Seo Lim ◽  
Miseo Kim ◽  
...  
Keyword(s):  
South Korea ◽  
Healthcare Workers ◽  
Adverse Reactions

scholarly journals Self-reported adverse reactions in 4337 healthcare workers immunizations against novel H1N1 influenza

2011 ◽  
Vol 4 (1) ◽  
Author(s):  
Harald Bias ◽  
David Quarcoo ◽  
Claus Meier-Wronski ◽  
Sabine Wicker ◽  
Joachim Seybold ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Adverse Reactions ◽  
H1n1 Influenza ◽  
Novel H1n1 Influenza

scholarly journals Healthcare workers’ reasons for choosing between two different COVID-19 prophylaxis trials in an acute pandemic context: Results from an online survey (Preprint)

2020 ◽  
Author(s):  
Alberto Borobia ◽  
Irene García-García ◽  
Lucía Díaz-García ◽  
Amelia Rodríguez-Mariblanca ◽  
Lucía Martínez de Soto ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Scientific Knowledge ◽  
Healthcare Workers ◽  
Online Survey ◽  
Adverse Reactions ◽  
Web Based ◽  
Main Motivation ◽  
Survey Participation ◽  
News Bulletin ◽  
Motivation To Participate

BACKGROUND In April 2020, two independent clinical trials (CT) to assess SARS-Cov-2 prophylaxis in healthcare workers were started in our Hospital: MeCOVID (melatonin vs placebo) and EPICOS (tenofovir disoproxil/emtricitabine vs hydroxychloroquine vs the combination of both vs placebo). OBJECTIVE We aim to evaluate the motivations to participate and the reasons to choose one or another. METHODS Both CTs were offered to personnel through the internal news bulletin. After the screening visit, all subjects were asked to answer a web-based survey. RESULTS In the first month, 206 healthcare workers were screened and 160 randomized. Survey participation was quite high, 73.3%. The main motivation to participate was “to contribute to scientific knowledge” 53.0%, followed by “to avoid SARS-Cov-2 infection” and “the interest to be tested for SARS-CoV-2”. We found differences between physicians and nurses in the expected personal benefits (P<0.05). The vast majority of the volunteers selected the MeCOVID study, the main reason was the fear of adverse reactions associated with treatments in EPICOS, 69.4%. CONCLUSIONS Healthcare workers´ motivations to participate in prophylaxis trials in a pandemic context appear to be driven mostly by their desire to contribute to science and getting some health benefits. Safety seems to weight way more than efficacy to choose between CTs.

scholarly journals Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea

2021 ◽  
Vol 36 (17) ◽  
Author(s):  
Seongman Bae ◽  
Yun Woo Lee ◽  
So Yun Lim ◽  
Ji-Hyang Lee ◽  
Joon Seo Lim ◽  
...  
Keyword(s):  
South Korea ◽  
Healthcare Workers ◽  
Adverse Reactions

scholarly journals Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers

2021 ◽  
pp. 1-6
Author(s):  
Filippos Filippatos ◽  
Elizabeth-Barbara Tatsi ◽  
Charilaos Dellis ◽  
Nick Dessypris ◽  
Vassiliki Syriopoulou ◽  
...  
Keyword(s):  
Healthcare Workers ◽  
Adverse Reactions ◽  
Short Term ◽  
Epidemiological Characteristics

scholarly journals Antibody Response to Live Attenuated Vaccines in Adults in Japan

Open Medicine ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. 482-488 ◽  
Author(s):  
Taku Ogawa ◽  
Fukumi Uchiyama-Nakamura ◽  
Aiko Sugata-Tsubaki ◽  
Yutaka Yamada ◽  
Kenji Uno ◽  
...  
Keyword(s):  
Single Dose ◽  
Antibody Titer ◽  
Healthcare Workers ◽  
Adverse Reactions ◽  
Varicella Vaccine ◽  
Limited Sample ◽  
Live Attenuated Vaccine ◽  
Post Vaccination ◽  
Vaccination Response ◽  
Severe Adverse Reactions

AbstractThe purpose of this study was to examine the efficacy rendered with a single dose of live attenuated measles, rubella, mumps, and varicella containing vaccine.We inoculated healthcare workers (HCWs) with a single dose of vaccine to a disease lacking in antibody titer for those not meeting the criteria of our hospital (measles: <16.0 (IgG enzyme immunoassay (EIA)), rubella: ≤1:32 (hemagglutination-inhibition), mumps: <4.0 (IgG EIA), and varicella: <4.0 (IgG EIA)). At 28–60 days after vaccination, the antibody titer was tested again.We included 48 HCWs. A total of 32, 15, 31, and 10 individuals were inoculated with a single dose of measles-containing, rubella-containing, mumps, or varicella vaccine, respectively, and showed significant antibody elevation (9.2 ± 12.3 to 27.6 ± 215.6, p<0.001; 8 ± 1.2 to 32 ± 65.5, p<0.001; 3.0 ± 1.0 to 13.1 ± 8.6, p<0.05; and 2.6 ± 1.3 to 11.8 ± 8.1, p<0.001, respectively). Major side effects were not observed.In a limited population, a single dose of live attenuated vaccine showed elevation of antibody titer without any severe adverse reactions. However, whether the post-vaccination response rate criteria of our university was fulfilled could not be determined owing to limited sample size.

scholarly journals Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

2021 ◽  
Author(s):  
Masaaki Takeuchi ◽  
Yukie Higa ◽  
Akina Esaki ◽  
Yosuke Nabeshima ◽  
Akemi Nakazono
Keyword(s):  
Antibody Production ◽  
Messenger Rna ◽  
Healthcare Workers ◽  
Adverse Reactions ◽  
Geometric Mean ◽  
Spike Protein ◽  
Igg Antibody ◽  
Blood Samples ◽  
Antibody Levels ◽  
Japanese Subjects

Adverse reactions are more common after the second injection of messenger RNA vaccines such as Pfizer/BioNTech's BNT162b2. We hypothesized that the degree and severity of reactogenicity after the second injection reflects the magnitude of antibody production against the SARS CoV-2 virus spike protein (spike IgG). Blood samples were obtained from 67 healthy Japanese healthcare workers three weeks after the first injection and two weeks after the second injection of the BNT162b2 vaccine to measure spike IgG levels. Using questionnaires, we calculated an adverse event (AE) score (0-11) for each participant. The geometric mean of spike IgG titers increased from 1,047 antibody units (AU/mL) (95% CI: 855±1282 AU/mL) after the first injection to 17,378 AU/mL (14,622±20,663 AU/mL) after the second injection. The median AE score increased from 2 to 5. Spike IgG levels after the second injection were negatively correlated with age and positively correlated with spike IgG after the first injection. AE scores after the second injection were not significantly associated with log-transformed spike IgG after the second injection, when adjusted for age, sex, and log-transformed spike IgG after the first injection. Although the sample size was relatively small, reactogenicity after the second injection may not accurately reflect antibody production.

Sign in / Sign up

Export Citation Format

Share Document